Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.41 per share a year ago.
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross
After reaching an important support level, Alector, Inc. (ALEC) could be a good stock pick from a technical perspective. ALEC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Alector (ALEC) Reports Q4 Loss, Beats Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.02 per share a year ago.
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.
Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector shares plunge after dementia drug fails to slow disease progression
Alector said on Tuesday its experimental drug failed to slow the progression of a rare form of dementia in a late-stage trial, prompting the company to end the study and cut nearly half its workforce.
Alector, Inc. - Special Call
Alector, Inc. - Special Call Company Participants Katie Hogan - Senior Director of Corporate Communication & Investor Relations Sara Kenkare-Mitra - President and Head of Research & Development Arnon Rosenthal - Co-Founder, CEO & Director Giacomo Salvadore - Chief Medical Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Myles Minter - William Blair & Company L.L.C., Research Division Thomas Shrader - BTIG, LLC, Research Division Steven Alexopoulos - TD Cowen, Research Division Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Alec Stranahan - BofA Securities, Research Division Graig Suvannavejh - Mizuho Securities USA LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Alector's conference call and webcast highlighting its progranulin franchise and Alector Brain Carrier programs.
After Golden Cross, Alector (ALEC)'s Technical Outlook is Bright
After reaching an important support level, Alector, Inc. (ALEC) could be a good stock pick from a technical perspective. ALEC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Alector, Inc. (ALEC) Q2 2025 Earnings Call Transcript
Alector, Inc. (NASDAQ:ALEC ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Arnon Rosenthal - Co-Founder, CEO & Director Giacomo Salvadore - Chief Medical Officer Katie Hogan - Senior Director of Corporate Communication & Investor Relations Neil Berkley - Interim CFO & Chief Business Officer Saraswati Kenkare-Mitra - President and Head of Research & Development Conference Call Participants Alec Warren Stranahan - BofA Securities, Research Division Michael H. Riad - Morgan Stanley, Research Division Myles Robert Minter - William Blair & Company L.L.C.
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.4 per share a year ago.
